intravitreal bevacizumab in the management of diabetic macular edema

diabetic macular edema (dme) is a leading cause of vision loss in the working-age population worldwide. numerous early studies suggest an important role for intravitreal anti-vegf agents such as bevacizumab in the management of dme. we reviewed manuscripts that had investigated pharmacokinetic, efficacy, safety, dose and frequency of intravitreal bevacizumab (ivb) injections as well as effect of macular ischemia, initial macular thickness and oct pattern of dme on the final results of treatment with ivb. in summery literature searches disclosed that almost all studies published up to now provided evidence supporting use of ivb for treatment of either naïve or persistent dme in short and long- term up to two years.